This page is updated frequently with new G Protein-related patent applications.
|| List of recent G Protein-related patents
|Expression tools for multiprotein applications|
Polynucleotides for multigene applications comprising a novel functional arrangement, as well as vectors, host cells, and recombinant animals comprising the polynucleotides are described. Methods for generating multigene expression cassettes, methods for producing multiprotein complexes in vitro and in vivo, and methods for producing a vaccine are also disclosed.
|Plants having one or more enhanced yield-related traits and a making the same|
A method for enhancing various economically important yield-related traits in plants. A method for enhancing one or more yield-related traits in plants by modulating expression in plants of a nucleic acid encoding a fkbp 16-3 (fk506-binding protein) or a quinone reductase-related (qrr) polypeptide.
|Means and methods for the generation of mammalian producer cells for the production of recombinant proteins|
The present invention relates to the generation of mammalian cells capable of producing proteins at an industrial scale and means and methods to obtain and use said cells, in particular for protein production.. .
|Novel acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer|
A novel gene 0161p2f10b (also designated 161p2f10b) and its encoded protein, and variants thereof, are described wherein 161p2f10b exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i. Consequently, 161p2f10b provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
|Methods and compositions relating to anti-il-21 receptor antibodies|
The present invention provides compositions and methods relating to antigen binding proteins against il-21 receptor.. .
|Tnf-alpha binding proteins|
Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (tnf-α), e.g., human tnf-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies..
|Process for preparing apolipoprotein a-i (apo a-i)|
The present invention relates to processes of obtaining apo a-1 from an apo a-1 containing protein fraction (a), comprising suspending—the apo a-1 containing protein fraction (a) in a buffer solution (b), removing impurities from the suspension while keeping the apo a-1 proteins solubilized, followed by precipitating apo a˜i from the suspension and collecting the apo a-1 precipitate. Apo a-i obtained by such processes, reconstituted hdl obtained from such apo a-1, and pharmaceutical compositions comprising such apo a-i and/or reconstituted hdl also are provided..
|Beverage lowering serum cholesterol|
A beverage comprising protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser.. .
|Non-glycosylated supar biomarkers and uses thereof|
Proteinuria markers and methods for their use are provided. These markers find many uses, including in diagnosing proteinuria, prognosing proteinuria, and treating proteinuria.
Rush University Medical Center
|Methods and compositions for enhancing targeted transgene integration|
Disclosed herein are methods and compositions for enhancing insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease or a hemophilia by administering one or more topoisomerases inhibitors, one or more stabilizers of r loop formation or inhibitors of r-loop repair and/or one or more up-regulators of the tc-ner pathway to the target cell.. .
Sangamo Biosciences, Inc.
Efficient displaying protein multimer
The invention provides a method of producing a protein multimer-nucleic acid complex comprising a protein multimer and any one target component of the protein multimer. A nucleic acid encoding the target component is subjected to in vitro translation to provide a translation product containing a target component-nucleic acid complex of the target component and the nucleic acid encoding the target component.
The present invention relates to means and methods for protecting proteins and protein-type compounds in industrial and other applications. In particular, the invention provides a composition comprising at least one protein or protein-type compound immobilized at the surface of a solid carrier embedded in a protective material.
Antibodies directed to her-3 and uses thereof
The present invention relates to binding proteins that bind to her-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided.
Composition and vaccine for treating lung cancer
The present invention relates to a composition comprising at least one mrna encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5t4 (trophoblast glycoprotein, tpbg), survivin (baculoviral tap repeat-containing protein 5; birc5), ny-eso-1 (new york esophageal squamous cell carcinoma 1, ctag1b), mage-c1 (melanoma antigen family c1), mage-c2 (melanoma antigen family c2), and muc1 (mucin 1). The invention furthermore relates to a vaccine comprising at least one mrna encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (nsclc), and diseases or disorders related thereto.
Methods and compositions for labeling polypeptides
Synthesis of many proteins is tightly controlled at the level of translation and plays an essential role in fundamental processes such as cell growth and proliferation, signaling, differentiation or death. Methods that allow imaging and identification of nascent proteins allow for dissecting regulation of translation, both spatially and temporally, including in whole organisms.
President And Fellows Of Harvard College
Chromatography matrices including novel staphylococcus aureus protein a based ligands
The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation
Inhibitors of transcription factors and uses thereof
The present invention provides novel compounds of any one of formulae (i) to (iv), and pharmaceutically compositions thereof. Compounds of any one of formulae (i) to (iv) are believed to be inhibitors of bromodomain-containing proteins (e.g., bromo and extra terminal proteins (bets)).
University Of Massachusetts
Vaccine formulations that induce a th2 immune response
The present invention relates to compositions and methods for the prevention and treatment of neurodegenerative diseases, such alzheimer's disease, that are caused by misfolding, aggregating proteins. The compositions and methods of the present invention comprise a vaccine formulation comprising an antigen selected from the group consisting of i) amyloid-β or a peptide that has in its amino acid sequence part of the amyloid-β amino acid sequence, ii) hyperphosphorylated tau protein or one of its hyperphoshorylated peptides, or iii) a combination of antigens derived from groups i) and ii) and that are formulated with a non-acylated or deacylated, natural or synthetic, bidesmosidic triterpene glycoside carrying an aldehyde or ketone group, which acts as an adjuvant or immune agonist.
Qantu Therapeutics, Inc.
Treatment of collagen defects using protein solutions
Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group il-1ra, stnf-ri, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii..
Biomet Biologics, Llc
Method of screening protein capable of binding to compound
Provided is a method of screening a protein capable of binding to a specific compound using gene ontology terms.. .
Samsung Electronics Co., Ltd.
Amdinocillin for rapid determination of susceptibility to beta-lactam antibiotics
Described are methods for detecting susceptibility of a specimen to antibiotics, and particularly for enhancing such susceptibility testing for beta lactam antibiotics and antibiotics that bind to penicillin-binding proteins. The method comprises contacting the specimen with an oligonucleotide probe that specifically hybridizes with a target nucleic acid sequence region of ribosomal rna.
United States Government Represented By The Department Of Veterans Affairs
Polymers and plastics derived from animal proteins
The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
The Governors Of The University Of Alberta
Novel dual-targeting protein binding specifically to dll4 and vegf and use thereof
The present invention relates to a novel dual-targeting protein comprising: a protein that binds specifically to delta-like ligand 4 (dll4); and an antibody that binds specifically to vascular endothelial cell growth factor (vegf).. .
Hanwha Chemical Corporation
Antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.
Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof
Non-naturally occurring factor h binding proteins derived from variant 3 fhbp that can elicit antibodies that are bactericidal for at least one strain of n. Meningitidis, and methods of use of such proteins, are provided.
Children's Hospital & Research Center Oakland
Apj receptor compounds
The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the g protein coupled receptor apelin, also known as the apj receptor. The apj receptor compounds are derived from the it intracellular loop and domain of the apj receptor.
Anchor Therapeutics, Inc.
Affinity tags and processes for purifying and immobilizing proteins using same
The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag.. .
University Of Washington Through Its Center For Commercialization
Crosslinking reagents, methods, and compositions for studying protein-protein interactions
The invention provides reagents, methods, and compositions for studying protein-protein interactions. The inventive system and methods allow the analysis of protein-protein interactions in vivo and in vitro.
Protein biomaterials and biocoacervates and methods of making and using thereof
The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g.
Gel-del Technologies, Inc.
Primecoat compositions for proteinaceous substrates and methods of priming proteinaceous substrates therewith
Compositions containing a solution of a polyfunctional aziridine component in a non-reactive solvent, and methods of applying such compositions to proteinaceous substrates, such as fingernails and toenails, to provide primed substrates which may be further coated.. .
Mad River Science
Method of predicting animal litter size using protein biomarkers related with fertility, and predicting animal sperm quality and litter size using chlortetracycline staining
The present invention relates to a method of predicting animal litter size using a fertility-related protein marker, and more particularly, to the discovery of a sperm marker that is expressed differently depending on animal fertility, a marker composition for predicting litter size, which comprises an antibody that binds specifically to the marker, and a method of predicting animal litter size using the marker composition. Moreover, the present invention relates to a method of predicting animal semen quality and litter size by chlortetracycline staining, and more particularly, to a method of predicting of animal litter size by measuring the motility, motion kinematics or capacitation status of sperm.
Chung Ang University Industry Academic Cooperation Foundation
Compounds and identifying, synthesizing, optimizing and profiling protein modulators
This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds.
Hmi Medical Innovations, Llc.
Instant view of protein bands
Apparatus, reagents, pre-treated proteins and methods for dying proteins in electrophoresis run gels, and for instantly viewing such dyed protein samples in an electrophoresis gel. A protein mixing solution containing a fluorescence dye is mixed with a protein sample so that fluorescence dyes within the protein mixing solution conjugate to proteins within the protein sample.
System and retrieval treatment of proteins in formalin-fixed paraffin-embedded tissue section
A protein retrieval treatment system used for activating proteins contained in a deparaffinized tissue section obtained by removing paraffin from a formalin-fixed paraffinembedded tissue section. The protein retrieval treatment system includes: a dispensing unit for dispensing a retrieval treatment solution over a dispensing area including a measurement area on the deparaffinized tissue section; and a moist-heat treatment unit for heating, in a saturated water vapor, the deparaffinized tissue section with the dispensing area covered with the retrieval treatment solution..
Antisense oligonucleotide compositions
The present invention relates to antisense oligonucleotide (aso) compositions and particularly to compositions and methods for the cytosolic delivery of antisense oligonucleotides (asos). Hybrid asos, part single-stranded and part double-stranded, are provided, hybridising to form a double-stranded region that can non-covalently bond to nucleic-acid-binding protein regions.
University Of Greenwich
Antibody binding sites specific for egfrviii
This application describes binding proteins that specifically bind to egfrviii and multispecific binding proteins that specifically bind to egfrviii and cd3. Further described is a multispecific tandem diabody that binds to egfrviii and cd3.
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, fab fragments, f(ab′)2 fragments, and single chain fv (scfv) fragments, as well as chimeric antigen receptors.
Memorial Sloan-kettering Cancer Center
Antigen binding proteins capable of binding thymic stromal lymphopoietin
The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (tslp), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-tslp antibodies and derivatives of such antibodies.
Mutated immunoglobulin-binding protein
The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at ph-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (cdr), such as protein a, and preferably the b-domain of staphylococcal protein a.
Ge Healthcare Bio-sciences Ab
Method of manufacturing d-galactose for use of the production of d-tagatose from whey permeate or dried whey permeate
A method for producing d-galactose from a dissolved solution of dried whey permeate or a liquid whey permeate is disclosed. The method comprises: removing non-sugar insoluble materials from the dissolved solution of dried whey permeate or the liquid whey permeate; removing protein from the dissolved solution of dried whey permeate or the liquid whey permeate from which non-sugar solid precipitates are removed; and removing ash, salts or both from the dissolved solution of dried whey permeate or the liquid whey permeate from which the proteins are removed.
Cj Cheiljedang Corporation
Low viscosity compositions comprising a pegylated gla-domain containing protein
The present invention relates to a method for lowering the viscosity of compositions comprising vitamin k-dependent proteins.. .
Novo Nordisk Healthcare Ag
Pharmaceutical compositions which inhibit fkbp52-mediated regulation of androgen receptor function and methods of using same
Pharmaceutical compositions that bind to a predicted fk506 binding protein 52 (fkbp52) interaction surface on the androgen receptor hormone binding domain, otherwise known as fkbp52 targeting agents (ftas) are provided. These compositions of the present invention are found to specifically recognize the fkbp52 regulatory surface on the androgen receptor and inhibit fkbp52 from functionally interacting with the androgen receptor.
The Board Of Regents Of The University Of Texas System
Rational solubilising proteins
A method and data processing system for identifying mutations or insertions that alter a property such as the solubility or aggregation propensity of an input polypeptide chain. The method comprises inputting a sequence of amino acids and a structure for said sequence for said target polypeptide chain; calculating a structurally corrected solubility or aggregation propensity profile for said target polypeptide chain; selecting, using said calculated profile, regions within said target polypeptide chain; identifying at least one position within each selected region suitable for mutations or insertions; generating a plurality of mutated sequences by mutations or insertions at least one identified position; and predicting a value of the solubility or aggregation propensity for each of the plurality of mutated sequences whereby any alteration to the solubility or aggregation propensity of the input polypeptide chain is identified.
Cambridge Enterprise Limited
Diagnostic testing in dementia and methods related thereto
This disclosure relates to diagnostic testing for subjects with or at risk of dementia and methods related thereto. In certain embodiments, the disclosure relates to methods of diagnosing a frontotemporal lobar degeneration subtype comprising measuring total tau and tau phosphorylated at threonine 181 in a sample from a subject, calculating a ratio of tau phosphorylated at threonine 181 to total tau, and making a diagnosis of the subtype based on said ratios.
Chemistry, systems and methods of translocation of a polymer through a nanopore
Embodiments disclosed herein are directed to recognition tunneling systems, methods and devices, and more particularly, to chemical reactions for selectively labeling proteins and peptides and placing protein and/or peptides into, or onto a nanopore formed in a solid support and threading such in and/or through the nanopore, with such nanopores, in some embodiments, including a molecular motor to pull or otherwise force the protein/peptide through the nanopore.. .
Arizona Board Of Regents Acting For And On Behalf Of Arizona State University
Genetically encoded sensors for imaging proteins and their complexes
Isolated truncated and mutated sensor proteins derived from flavoproteins that are 12-20 kda or less, genetically encoded for detection and imaging of protein complexes having long fluorescent lifetimes that can be 4.0 ns or greater.. .
President And Board Of Trustees Of Santa Clara College
Peptide-presenting protein and peptide library using same
The object of the present invention is to provide a method for screening peptide(s) highly specific to a target molecule. The object can be solved by a peptide-presenting protein wherein a peptide is presented in a presentation region consisting of the 131st to 139th amino acids in the amino acid sequence of the seq id no: 54, wherein the peptide consisting of 4 to 15 amino acids is inserted in the 131st to 139th amino acids sequence, or substituted for any of 1 to 9 amino acid(s) sequence in the 131st to 139th amino acids sequence; and a total length of an amino acid sequence corresponding to the 131st to 139th amino acids sequence is 15 or less..
Tokyo Institute Of Technology
Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
Cb-1 receptor antigen-binding proteins and uses thereof
This disclosure relates to cb1 receptor antigen-binding proteins, e.g. Antibodies and methods of using the cb1 receptor antibodies.
Il-21 binding proteins and uses thereof
The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-21 (il-21) and uses thereof, e.g., in therapy.. .
Human antibodies binding to rsv g proteins
The disclosure provides isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv.. .
Crucell Holland B. V.
Human antibodies binding to rsv g protein
The disclosure relates to isolated antibodies and antigen-binding fragments that bind to the g protein of rsv and which are capable of neutralizing rsv a and b subtypes, and the use thereof in the diagnosis, prophylaxis, and/or treatment of rsv infections.. .
Crucell Holland B.v.
Carriers for improved drug delivery
The invention provides carriers that enhance the absorption, half-life or bioavailability of therapeutic compounds. The carriers comprise targeting groups that bind the vitamin d binding protein (dbp), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties..
Extend Biosciences, Inc.
Design and development of masked therapeutic antibodies to limit off-target effects
In one embodiment, a masked monoclonal antibody (mab) is provided, the mab, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mab) is provided, which includes a therapeutic mab and a mask, the mask comprising protein a and protein l attached by a protease cleavable linker..
City Of Hope
Methods for controlling fucosylation levels in proteins
The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions..
Center Of Molecular Immunology
Novel genes involved in biosynthesis
The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited
Oncostatin m receptor antigen binding proteins
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.
Method for refining protein including self-cutting cassette and use thereof
The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by lpxtg, a domain of sortase a having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method..
Scripps Korea Antibody Institute
Il-1 family variants
The present invention provides compositions and methods relating to il-1rrp2 requiring proteins.. .
Thiazole inner salt compounds, and preparation methods and uses thereof
The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of formula i, hydrates or pharmaceutically acceptable salts thereof.
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China
Methods of treating pain using protein solutions
Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level.
Method for producing autologous proteins
A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
Computer-implemented methods of determining protein viscosity
The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag
Novel antigen binding protein and its use as addressing product for the treatment of cancer
The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to axl and, by inducing internalization of axl, being internalized into the cell.
Pierre Fabre Medicament